Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion

Du,Nan; Li,Xiaosong; Li,Fang; Zhao,Hui; Fan,Zhongyi; Ma,Junxun; Fu,Yan; Kang,Huanrong

doi:10.3892/or.2013.2349

Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion

Authors:
- Nan Du
- Xiaosong Li
- Fang Li
- Hui Zhao
- Zhongyi Fan
- Junxun Ma
- Yan Fu
- Huanrong Kang
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, P.R. China, Cancer Center, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: March 15, 2013 https://doi.org/10.3892/or.2013.2349
Pages: 2332-2340

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the present study was to evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab and cisplatin, an antineoplastic agent, in controlling MPE. A total of 72 NSCLC study subjects with MPE were randomly assigned to one of two groups. The first group received intrapleural bevacizumab (300 mg) with cisplatin (30 mg) therapy and the second group received intrapleural cisplatin (30 mg) therapy alone. Pleural fluid was collected from both groups prior to and following treatment. The levels of VEGF and carcinoembryonic antigen (CEA) in the pleural fluid were determined by ELISA. In 70 evaluable study subjects, the curative efficacy in the bevacizumab group was significantly higher than that found in the cisplatin group (83.33 vs. 50.00%, respectively; p<0.05). Therapy with combined bevacizumab plus cisplatin significantly reduced VEGF levels in the pleural fluid (p<0.01). In the bevacizumab group, the levels of VEGF in the pleural fluid were significantly lower compared to those of the cisplatin group after treatment, which showed greater efficacy (p<0.01). In addition, combination therapy showed greater efficacy in the patients with high levels of VEGF expression (p<0.01). There was no significant difference in grade III/IV adverse events between the two groups. All procedures were well tolerated by the patients. Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC-mediated MPE. We propose that VEGF expression levels in MPE could serve as a prognostic marker for bevacizumab therapy.

View Figures

View References

1	Sanz N, Aguado P, de Agustin JC, et al: Parapneumonic effussion. A review of 33 cases over 6 years. Cir Pediatr. 18:77–82. 2005.(In Spanish).
2	Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 13(Suppl 1): 5–13. 2008. View Article : Google Scholar : PubMed/NCBI
3	Masuno T, Kishimoto S, Ogura T, et al: A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer. 68:1495–1500. 1991. View Article : Google Scholar : PubMed/NCBI
4	Rusch VW, Figlin R, Godwin D and Piantadosi S: Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol. 9:313–319. 1991.PubMed/NCBI
5	Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ and Lee LN: Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer. 69:674–679. 1992. View Article : Google Scholar : PubMed/NCBI
6	Tohda Y, Iwanaga T, Takada M, et al: Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy. 45:197–204. 1999. View Article : Google Scholar : PubMed/NCBI
7	Ishida A, Miyazawa T, Miyazu Y, et al: Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer. Respirology. 11:90–97. 2006. View Article : Google Scholar : PubMed/NCBI
8	Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar
9	Fontanini G, Faviana P, Lucchi M, et al: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 86:558–563. 2002. View Article : Google Scholar : PubMed/NCBI
10	Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 25:600–604. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C and Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 14:1242–1251. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
13	Pichelmayer O, Zielinski C and Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 353:740–741. 2005. View Article : Google Scholar : PubMed/NCBI
14	Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 54:1–9. 2006. View Article : Google Scholar : PubMed/NCBI
15	Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ribeiro SC, Vargas FS, Antonangelo L, et al: Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology. 14:1188–1193. 2009.
17	Teixeira LR, Vargas FS, Acencio MM, et al: Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer. 74:392–395. 2011. View Article : Google Scholar : PubMed/NCBI
18	Pichelmayer O, Gruenberger B, Zielinski C and Raderer M: Bevacizumab is active in malignant effusion. Ann Oncol. 17:18532006. View Article : Google Scholar : PubMed/NCBI
19	Sahn SA: Management of malignant pleural effusions. Monaldi Arch Chest Dis. 56:394–399. 2001.PubMed/NCBI
20	Musani AI: Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 15:380–387. 2009. View Article : Google Scholar : PubMed/NCBI
21	Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW and McVie JG: Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49:3380–3384. 1989.PubMed/NCBI
22	Walker-Renard PB, Vaughan LM and Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 120:56–64. 1994. View Article : Google Scholar : PubMed/NCBI
23	Aslam N and Marino CR: Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 161:2733–2737. 2001. View Article : Google Scholar : PubMed/NCBI
24	Grove CS and Lee YC: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 8:294–301. 2002. View Article : Google Scholar : PubMed/NCBI
25	Patane S, Marte F, Di Bella G and Davi M: Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass. Int J Cardiol. 127:e105–e107. 2008. View Article : Google Scholar : PubMed/NCBI
26	Yokoyama T, Tanaka A, Kato S and Aizawa H: Multiple myeloma presenting initially with pleural effusion and a unique paraspinal tumor in the thorax. Intern Med. 47:1917–1920. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chen Y, Liang B, Zhao YJ, Wang SC, Fan YB and Wu GP: Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol. 40:287–291. 2012. View Article : Google Scholar : PubMed/NCBI
28	Folkman J, Merler E, Abernathy C and Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 133:275–288. 1971. View Article : Google Scholar : PubMed/NCBI
29	Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE and Antony VB: Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 281:L119–L125. 2001.PubMed/NCBI
30	Folkman J: Tumor angiogenesis and tissue factor. Nat Med. 2:167–168. 1996. View Article : Google Scholar
31	Zebrowski BK, Yano S, Liu W, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 5:3364–3368. 1999.PubMed/NCBI
32	Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 193:468–475. 2001. View Article : Google Scholar : PubMed/NCBI
33	Presta LG, Chen H, O’Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593–4599. 1997.PubMed/NCBI
34	Shaheen RM, Tseng WW, Vellagas R, et al: Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol. 18:221–226. 2001.
35	Hama M, Komatsu Y and Hachiya T: A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel. Gan To Kagaku Ryoho. 38:1877–1879. 2011.(In Japanese).
36	Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 102:425–428. 2006. View Article : Google Scholar : PubMed/NCBI
37	Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 111:530–532. 2008. View Article : Google Scholar : PubMed/NCBI
38	Kesterson JP, Mhawech-Fauceglia P and Lele S: The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol. 111:527–529. 2008. View Article : Google Scholar : PubMed/NCBI
39	Volm M, Koomagi R and Mattern J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 74:64–68. 1997. View Article : Google Scholar : PubMed/NCBI
40	Kassim SK, El-Salahy EM, Fayed ST, et al: Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 37:363–369. 2004. View Article : Google Scholar : PubMed/NCBI
41	Kumar H, Heer K, Lee PW, et al: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 4:1279–1285. 1998.PubMed/NCBI
42	Matsuyama W, Hashiguchi T, Mizoguchi A, et al: Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest. 118:948–951. 2000. View Article : Google Scholar : PubMed/NCBI
43	Cheng D, Rodriguez RM, Perkett EA, et al: Vascular endothelial growth factor in pleural fluid. Chest. 116:760–765. 1999. View Article : Google Scholar : PubMed/NCBI
44	Kraft A, Weindel K, Ochs A, et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 85:178–187. 1999. View Article : Google Scholar : PubMed/NCBI
45	Thickett DR, Armstrong L and Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax. 54:707–710. 1999. View Article : Google Scholar : PubMed/NCBI
46	Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H and Sone S: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 48:396–400. 1999. View Article : Google Scholar : PubMed/NCBI
47	Verheul HM, Hoekman K, Jorna AS, Smit EF and Pinedo HM: Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 5(Suppl 1): 45–50. 2000. View Article : Google Scholar : PubMed/NCBI
48	Ishimoto O, Saijo Y, Narumi K, et al: High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology. 63:70–75. 2002. View Article : Google Scholar : PubMed/NCBI
49	Kishiro I, Kato S, Fuse D, Yoshida T, Machida S and Kaneko N: Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology. 7:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
50	Momi H, Matsuyama W, Inoue K, et al: Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med. 96:817–822. 2002. View Article : Google Scholar : PubMed/NCBI
51	Harlozinska A, Sedlaczek P, Kulpa J, et al: Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 24:1149–1157. 2004.PubMed/NCBI
52	Rudlowski C, Pickart AK, Fuhljahn C, et al: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 16(Suppl 1): 183–189. 2006. View Article : Google Scholar : PubMed/NCBI
53	Watanabe M, Boyer JL and Crystal RG: AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 17:1042–1051. 2010. View Article : Google Scholar : PubMed/NCBI
54	Konner JA, Grabon DM, Gerst SR, et al: Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 29:4662–4668. 2011. View Article : Google Scholar